Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996

Kidney International

Volumn 54, Issue 6, 1998, Pages 2129-2139

  Cotter, Dennis J ^a   Thamer, Mae ^b   Kimmel, Paul L ^b   Sadler, John H ^b  

^a Minneapolis Med Research Foundation   (United States)

^b NONE

Author keywords

Anemia; Chronic renal failure; End stage renal disease; Hematocrit; Hemodialysis; Medicare; Practice patterns; Recombinant human erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; FEMALE; FOOD AND DRUG ADMINISTRATION; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEGRO; NON PROFIT HOSPITAL; PRIORITY JOURNAL; RACE DIFFERENCE; REIMBURSEMENT; UNITED STATES;

EID: 0031754712     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00187.x     Document Type: Article

References (40)

1. ESCHBACH JW, ABDULHADI MH, BROWNE JK, DELANO BG, DOWNING MR, EGRIE JC, EVANS RW, FRIEDMAN EA, GRABER SE, HALY R, KORBET S, KRANIS SB, LUNDIN AP, NISSENSON AR, OGDEN DA, PAGANINI EP, RADER B, RUTSKY EA, STIVELMAN J, STONE WJ, TESCHAN P, VANSTONE JC, VANWYCK DB, ZUCKERMAN K, ADAMSON JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multiccnter clinical trial. Ann Intern Med 111:992-1000, 1989
2. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
3. U.S. Renal Data System: USRDS 1995 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, April 1995
4. GRIFFITHS RI, POWE NR, GREER JW, DE LISSOVOY G, ANDERSON GF, WHELTON PK, WATSON AJ, EGGERS PW: A review of the first year of Medicare coverage of erythropoietin. Health Care Fin Rev 15:83-102, 1994
5. U.S. RENAL DATA SYSTEM: USRDS 1997 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, April 1997
6. THAMER M, RICHARD C, RAY NF, GREER JW, COTTER DJ, PEARSON BC: The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. Am J Kidney Dis 28:235-249, 1996
7. NISSENSON AR: National cooperative rHu erythropoietin study in patients with chronic renal failure: A phase IV multicenter study. Am J Kidney Dis 18:24-33, 1991
8. EGGERS PW, GREER J, JENCKS S: The use of health care financing administration data for the development of a quality improvement project on the treatment of anemia. Am J Kidney Dis 24:247-254, 1994
9. SISK JE, GIANFRANCESCO FD, COSTER JM: Recombinant erythropoietin and medicare payment. JAMA 266:247-252, 1991
10. POWE NR, GRIFFITHS RI, ANDERSON GF, DELISSOVOY G, WATSON AJ, GREER JW, HERBERT RJ, WHELTON PK: Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis 22:557-567, 1991
11. Personal communication with Joel Greer, PhD, Senior Economist, Office of Research, Demonstrations, Health Care Financing Administration, September, 1997
12. PETRONIS KR, CARROLL CE, HELD PJ, PORT FK: Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA 271:1760-1763, 1994
13. POWE NR, GRIFFITHS RI, DELISSOVOY G, ANDERSON GF, WATSON AJ, GREER JW, HERBERT RJ, EGGERS PW, MILAM RA, WHELTON PK: Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 268:1434-1440, 1992
14. PROSPECTIVE PAYMENT ASSESSMENT COMMISSION: End-Stage Renal Disease payment policy. Congressional Report C-92-04. June 1992
15. DELISSOVOY G, POWE NR, GRIFFITHS RI, WATSON AJ, ANDERSON GF, GREER JW, HERBERT RJ, EGGERS PW, MILAM RA, WHELTON PK: The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care 32:130-140, 1994
16. POWE NR, GRIFFITHS RI, GREEK JW, WATSON AJ, ANDERSON GF, DE LISSOVOY G, HERBERT RJ, EGGERS PW, MILAM RA, WHELTON PK: Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 43:1125-1133, 1993
17. ESCHBACH JW: The future of r-HuEPO. Nephrol Dial Transplant 10:96-109, 1995
18. TARNG DC, CHEN TW, HUANG TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
19. BECKER BN, KOURY MJ: Resistance to erythropoietin in dialysis patients: Factors that decrease erythropoietin responsiveness. Dial Transplant 22:686-707, 1993
20. KOURY MJ: Investigating erythropoietin resistance. N Engl J Med 328:205-206, 1993
21. RAO DS, SHIH M, MOHINI R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
22. ADAMSON JW: The relationship of erythropoietin and iron metabo-lism to red blood cell production in humans. Semin Oncol 21:9-15, 1994
23. VANWYCK DB, STIVELMAN JC, RUIZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
24. WINGARD RL, PARKER RA, ISMAIL N, HAKIM RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995
25. RAKEL RE (editor): Conn's Current Therapy, 1995. Philadelphia, W.B. Saunders Company, 1995
26. STEIN JH (editor-in-chief): Internal Medicine (4th ed). St. Louis, Mosby-Year Book, Inc., 1994
27. HEALTH CARE FINANCING ADMINISTRATION: The Anemia Cooperative Project: A Practical Guide to Improving Care in Hemodialysis Patients. Working draft. July, 1994
28. DRUEKE TB, BARANY P, CAZZOLA M, ESCHBACH JW, GRUTZMACHER P, KALTWASSER JP, MACDOUGALL IC, PIPPARD MJ, SHALDON S, VAN WYCK D: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated pa-tients. Clin Nephrol 48:1-8, 1997
29. U.S. RENAL DATA SYSTEM: USRDS 1996 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1996
30. HEALTH CARE FINANCING ADMINISTRATION: Annual Report, End Stage Renal Disease Core Indicators Project. Baltimore, Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, December, 1997
31. HARINA JH, SCHWABERGER G, BRUSSEE H, SAUSENG-FELLEGGER G, HOLZER H, KREJS GJ: Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Tranplant 8:1219-1222, 1993
32. BRAUMANN KM, NONNAST-DANIEL B, BONING D, BACKER A, FREI U: Improved physical performance after treatment of renal anemia with recombinant erythropoeitin. Nephron 58:129-134, 1991
33. ROBERTSON HT, HALEY NR, GUTHRIE M, CARDENAS D, ESCHBACH JW, ADAMSON JW: Recombinant erythropoeitin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15:325-332, 1990
34. MAYER G, THUM J, CADA EM, STUMMVOLL HK, GRAF H: Working capacity is increased following recombinant human erythropoeitin treatment. Kidney Int 34:525-528, 1988
35. WIZEMAN V, SCHAFER R, KRAMER W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 64:202-206, 1993
36. WOLCOTT DL, MARSH JT, LA RUE A, CARR C, NISSENSON AR: Recombinant human erythropoeitin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14:478-485, 1989
37. SCHAFER RM, KOKOT F, HEIDLAND A: Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 76:273-282, 1989
38. NFK-DOQI CLINICAL PRACTICE: Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York, National Kidney Foundation, 1997
39. EVANS RW, RADER B, MANNINEN DL: The quality of life of hemodialysis patients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
40. BEURSTERIEN KM, NISSENSON AR, PORT FK, KELLY M, STEINWALD B, WARE JE JR: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7:763-773, 1996